En-face quantitative evaluation using ultra-high-resolution OCT of hyperreflective foci in neovascular age-related macular degeneration.

IF 2.1 3区医学 Q2 OPHTHALMOLOGY

Japanese Journal of Ophthalmology Pub Date : 2025-06-12 DOI:10.1007/s10384-025-01219-x

Iori Wada, Shintaro Nakao, Satomi Shiose, Yoshihiro Kaizu, Muneo Yamaguchi, Keijiro Ishikawa, Kohei Kiyohara, Tatsuro Ishibashi, Koh-Hei Sonoda

{"title":"En-face quantitative evaluation using ultra-high-resolution OCT of hyperreflective foci in neovascular age-related macular degeneration.","authors":"Iori Wada, Shintaro Nakao, Satomi Shiose, Yoshihiro Kaizu, Muneo Yamaguchi, Keijiro Ishikawa, Kohei Kiyohara, Tatsuro Ishibashi, Koh-Hei Sonoda","doi":"10.1007/s10384-025-01219-x","DOIUrl":null,"url":null,"abstract":"Purpose: This study quantifies hyperreflective foci (HRFs) in neovascular age-related macular degeneration (nAMD) before and after anti-VEGF therapy in the initial loading phase using en-face ultra-high-resolution spectral domain OCT (UHR-SD-OCT), investigating their correlation with clinical findings.Study design: Retrospective observational study METHODS: This retrospective study included 30 eyes from 30 patients with treatment-naïve nAMD. The patients received monthly intravitreal injections of anti-VEGF therapy for three months as the initial loading phase. At each visit, comprehensive ophthalmic examinations were conducted. HRFs were quantified using our custom-developed software from an en-face UHR-SD-OCT. The number of HRFs was compared before and after the loading phase and investigated the relationship with best-corrected visual acuity (BCVA), greatest linear dimension (GLD), macular neovascularization (MNV) size and incidence of macular atrophy (MA).Results: This evaluation system showed a significant reduction in the number of HRFs after anti-VEGF therapy compared to before the loading phase (p < 0.0001). The number of pre-treatment HRFs significantly correlated with pre-treatment BCVA, GLD, and MNV size. The number of post-treatment HRFs significantly correlated with pre-treatment GLD and pre-treatment MNV size. Additionally, patients who developed MA two years after treatment initiation exhibited significantly higher counts of pre-treatment HRFs compared to those without the MA development (465.7 ± 187.0 vs. 212.9 ± 93.8, p < 0.05).Conclusions: Quantification of HRF using en-face UHR-SD-OCT may be a useful clinical biomarker during anti-VEGF therapy in nAMD.","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10384-025-01219-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study quantifies hyperreflective foci (HRFs) in neovascular age-related macular degeneration (nAMD) before and after anti-VEGF therapy in the initial loading phase using en-face ultra-high-resolution spectral domain OCT (UHR-SD-OCT), investigating their correlation with clinical findings.

Study design: Retrospective observational study METHODS: This retrospective study included 30 eyes from 30 patients with treatment-naïve nAMD. The patients received monthly intravitreal injections of anti-VEGF therapy for three months as the initial loading phase. At each visit, comprehensive ophthalmic examinations were conducted. HRFs were quantified using our custom-developed software from an en-face UHR-SD-OCT. The number of HRFs was compared before and after the loading phase and investigated the relationship with best-corrected visual acuity (BCVA), greatest linear dimension (GLD), macular neovascularization (MNV) size and incidence of macular atrophy (MA).

Results: This evaluation system showed a significant reduction in the number of HRFs after anti-VEGF therapy compared to before the loading phase (p < 0.0001). The number of pre-treatment HRFs significantly correlated with pre-treatment BCVA, GLD, and MNV size. The number of post-treatment HRFs significantly correlated with pre-treatment GLD and pre-treatment MNV size. Additionally, patients who developed MA two years after treatment initiation exhibited significantly higher counts of pre-treatment HRFs compared to those without the MA development (465.7 ± 187.0 vs. 212.9 ± 93.8, p < 0.05).

Conclusions: Quantification of HRF using en-face UHR-SD-OCT may be a useful clinical biomarker during anti-VEGF therapy in nAMD.

查看原文本刊更多论文

使用超高分辨率OCT对新生血管性年龄相关性黄斑变性的高反射灶进行定量评价。

目的：本研究使用面面超高分辨率光谱域OCT （UHR-SD-OCT）量化初始加载阶段抗vegf治疗前后新生血管性年龄相关性黄斑变性（nAMD）的高反射灶（hyperreflective focal, hrf），探讨其与临床表现的相关性。研究设计：回顾性观察性研究方法：本回顾性研究包括30例treatment-naïve nAMD患者的30只眼睛。患者每月接受玻璃体内注射抗vegf治疗，为期3个月作为初始加载期。每次就诊均进行全面眼科检查。使用我们定制的软件从正面UHR-SD-OCT中量化hrf。比较加载前后hrf数与最佳矫正视力（BCVA）、最大线性维数（GLD）、黄斑新生血管（MNV）大小和黄斑萎缩（MA）发生率的关系。结果：该评估系统显示，与加载期前相比，抗vegf治疗后HRFs数量显著减少（p < 0.0001）。预处理hrf数与预处理BCVA、GLD、MNV大小显著相关。治疗后hrf数与治疗前GLD、MNV大小显著相关。此外，治疗开始两年后发生MA的患者的治疗前HRFs计数明显高于未发生MA的患者（465.7±187.0比212.9±93.8,p < 0.05）。结论：在nAMD患者抗vegf治疗过程中，使用正面UHR-SD-OCT定量HRF可能是一个有用的临床生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Japanese Journal of Ophthalmology 医学-眼科学

CiteScore

4.80

自引率

8.30%

发文量

审稿时长

6-12 weeks

期刊介绍： The Japanese Journal of Ophthalmology (JJO) was inaugurated in 1957 as a quarterly journal published in English by the Ophthalmology Department of the University of Tokyo, with the aim of disseminating the achievements of Japanese ophthalmologists worldwide. JJO remains the only Japanese ophthalmology journal published in English. In 1997, the Japanese Ophthalmological Society assumed the responsibility for publishing the Japanese Journal of Ophthalmology as its official English-language publication. Currently the journal is published bimonthly and accepts papers from authors worldwide. JJO has become an international interdisciplinary forum for the publication of basic science and clinical research papers.